Amferia kills bacteria

Amferia is a young Swedish medtech company founded in 2018 with the ambitious goal of tackling the global threat of antibiotic resistance. They have developed a unique antimicrobial technology platform based on bioinspired and amphiphilic antibacterial polymers that rapidly kill bacteria upon contact, even those resistant to antibiotics. Their technology is highly selective, targeting only bacteria while being non-toxic to human and animal cells.

Amferia's first product is a wound care dressing for animals, which has undergone successful clinical testing in Europe and has already been launched in Sweden. The company is currently expanding into other markets and is preparing to launch its human wound care product. Amferia is also exploring other potential applications for their technology, including spray-based products for wound care and coatings for medical devices. Their goal is to create a sustainable solution to combat antibiotic resistance by providing safer and more effective antimicrobial alternatives.

Amferia is a medical device company focused on developing a new class of antimicrobial materials that combat the global threat of antibiotic resistance. Their innovative platform technology utilizes bio-inspired antimicrobial peptides, safely encased in a patented hydrogel, to rapidly kill bacteria, even resistant strains, without harming the body. Their mission is to revolutionize wound care, prevent infections in medical devices, and ultimately provide safer and more effective treatments for patients at risk of acquiring dangerous bacterial infections.

Amferia promotes a culture of scientific rigor and innovation, grounded in fundamental research and a commitment to evidence-based approaches. This translates into a workplace that values critical thinking, asking good questions, and a willingness to learn. Amferia's fast-growing environment encourages collaboration and a sense of purpose, driven by the shared vision of tackling antibiotic resistance and bringing impactful products to patients worldwide.